Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

The p53 isoform delta133p53ß regulates cancer cell apoptosis in a RhoB-dependent manner.

Arsic N, Ho-Pun-Cheung A, Evelyne C, Assenat E, Jarlier M, Anguille C, Colard M, Pezet M, Roux P, Gadea G.

PLoS One. 2017 Feb 17;12(2):e0172125. doi: 10.1371/journal.pone.0172125. eCollection 2017. Erratum in: PLoS One. 2017 Apr 6;12 (4):e0175607.

2.

In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells.

Giudice V, Ricci P, Marino L, Rocco M, Villani G, Langella M, Manente L, Seneca E, Ferrara I, Pezzullo L, Serio B, Selleri C.

Transl Med UniSa. 2016 Nov 1;15:22-33. eCollection 2016 Nov.

3.

Simultaneous irradiation of fibroblasts and carcinoma cells repress the secretion of soluble factors able to stimulate carcinoma cell migration.

Arshad A, Deutsch E, Vozenin MC.

PLoS One. 2015 Jan 30;10(1):e0115447. doi: 10.1371/journal.pone.0115447. eCollection 2015.

4.

Protein prenylation and synaptic plasticity: implications for Alzheimer's disease.

Hottman DA, Li L.

Mol Neurobiol. 2014 Aug;50(1):177-85. doi: 10.1007/s12035-013-8627-z. Epub 2014 Jan 5. Review.

5.

Expression loss and revivification of RhoB gene in ovary carcinoma carcinogenesis and development.

Liu Y, Song N, Ren K, Meng S, Xie Y, Long Q, Chen X, Zhao X.

PLoS One. 2013 Nov 1;8(11):e78417. doi: 10.1371/journal.pone.0078417. eCollection 2013.

6.

Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia.

Wojciak-Stothard B, Zhao L, Oliver E, Dubois O, Wu Y, Kardassis D, Vasilaki E, Huang M, Mitchell JA, Harrington LS, Prendergast GC, Wilkins MR.

Circ Res. 2012 May 25;110(11):1423-34. doi: 10.1161/CIRCRESAHA.112.264473. Epub 2012 Apr 26. Erratum in: Circ Res. 2012 Aug 17;111(5):e163. Louise, Harrington [corrected to Harrington, Louise S].

7.

Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells.

Krzykowska-Petitjean K, Małecki J, Bentke A, Ostrowska B, Laidler P.

J Cancer Res Clin Oncol. 2012 Mar;138(3):537-44. doi: 10.1007/s00432-011-1131-9. Epub 2011 Dec 31.

8.

Breast cancer stem cells survive periods of farnesyl-transferase inhibitor-induced dormancy by undergoing autophagy.

Chaterjee M, van Golen KL.

Bone Marrow Res. 2011;2011:362938. doi: 10.1155/2011/362938. Epub 2011 Jul 7.

9.

Targeting protein prenylation for cancer therapy.

Berndt N, Hamilton AD, Sebti SM.

Nat Rev Cancer. 2011 Oct 24;11(11):775-91. doi: 10.1038/nrc3151. Review.

10.

A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.

Wong NS, Meadows KL, Rosen LS, Adjei AA, Kaufmann SH, Morse MA, Petros WP, Zhu Y, Statkevich P, Cutler DL, Meyers ML, Hurwitz HI.

Cancer Invest. 2011 Nov;29(9):617-25. doi: 10.3109/07357907.2011.621912.

11.

The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RhoB-mediated cell death after DNA damage.

Srougi MC, Burridge K.

PLoS One. 2011 Feb 23;6(2):e17108. doi: 10.1371/journal.pone.0017108.

12.

Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents.

Fletcher S, Keaney EP, Cummings CG, Blaskovich MA, Hast MA, Glenn MP, Chang SY, Bucher CJ, Floyd RJ, Katt WP, Gelb MH, Van Voorhis WC, Beese LS, Sebti SM, Hamilton AD.

J Med Chem. 2010 Oct 14;53(19):6867-88. doi: 10.1021/jm1001748.

13.

Palmitoylation of oncogenic NRAS is essential for leukemogenesis.

Cuiffo B, Ren R.

Blood. 2010 Apr 29;115(17):3598-605. doi: 10.1182/blood-2009-03-213876. Epub 2010 Mar 3.

14.

Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice.

DeWard AD, Leali K, West RA, Prendergast GC, Alberts AS.

PLoS One. 2009 Sep 21;4(9):e7102. doi: 10.1371/journal.pone.0007102.

15.

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.

Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, Dent P, Grant S.

Blood. 2008 Sep 15;112(6):2439-49. doi: 10.1182/blood-2008-05-159392. Epub 2008 Jul 9.

16.

Ras oncogenes: split personalities.

Karnoub AE, Weinberg RA.

Nat Rev Mol Cell Biol. 2008 Jul;9(7):517-31. doi: 10.1038/nrm2438. Review.

17.

Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.

Haas-Kogan DA, Banerjee A, Kocak M, Prados MD, Geyer JR, Fouladi M, McKnight T, Poussaint TY, Broniscer A, Blaney SM, Boyett JM, Kun LE.

Neuro Oncol. 2008 Jun;10(3):341-7. doi: 10.1215/15228517-2008-004. Epub 2008 Apr 16.

18.

ROCK I-mediated activation of NF-kappaB by RhoB.

Rodriguez PL, Sahay S, Olabisi OO, Whitehead IP.

Cell Signal. 2007 Nov;19(11):2361-9. Epub 2007 Aug 8.

19.

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE.

Blood. 2007 Feb 15;109(4):1387-94. Epub 2006 Nov 2.

20.

Rho2 is a target of the farnesyltransferase Cpp1 and acts upstream of Pmk1 mitogen-activated protein kinase signaling in fission yeast.

Ma Y, Kuno T, Kita A, Asayama Y, Sugiura R.

Mol Biol Cell. 2006 Dec;17(12):5028-37. Epub 2006 Sep 27.

Supplemental Content

Support Center